Although TNFα targeting was presented as a promising therapy in PDAC to overcome its effects in immune evasion61 and tumour evolution,57 its application in clinical trials was not effective.62 63 Thus, targeting TNFα-related molecules instead might lead to more effective treatments as has been recently proposed.64 Since the available PGLYRP1 KO mouse is viable and only shows increased susceptibility to intraperitoneal infections,65 exploring the development of therapies to target PGLYRP1 as a potential immunotherapeutic approach should be considered. The gene discussed is PGLYRP1; the disease is neoplasm.